文献速递脊柱关节炎

评估生物制剂联合与不联合甲氨蝶呤治疗银屑病关节炎的疗效:一项网络荟萃分析

Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.
PubMed 文献 · RMD Open · 2024-01-31

该系统综述与贝叶斯网络荟萃分析比较了生物制剂单药与联合甲氨蝶呤治疗成人活动性银屑病关节炎的疗效。共17项随机双盲对照试验纳入分析,结果显示在ACR20/50应答上,生物制剂单药与联合甲氨蝶呤无统计学显著差异。

要点

  • 在ACR20应答上,所有活性治疗均显著优于安慰剂。
  • 生物制剂单药与联合甲氨蝶呤在ACR20/50应答上无统计学显著差异。
  • IL-17抑制剂在ACR20应答上显著优于TNF抑制剂,与IL-23抑制剂相当。

核心结论

  • 甲氨蝶呤与生物制剂联用并未改善ACR疗效结局,相比生物制剂单药治疗。
  • 在银屑病关节炎患者中,使用生物制剂以达到ACR20/50应答时,甲氨蝶呤似乎并非必要的背景治疗。

研究设计与样本

  • 系统文献综述识别随机双盲对照试验,共初始识别31项研究,其中17项符合网络荟萃分析可行性标准(包含「不联合甲氨蝶呤」亚组)。
  • 采用贝叶斯网络荟萃分析,按治疗类别(TNF抑制剂、IL-23抑制剂、IL-17抑制剂)比较生物制剂联合与不联合甲氨蝶呤。
  • 疗效结局包括ACR20、ACR50和ACR70改善应答。

主要发现

  • 对于ACR20疗效(所考察的最稳健评估),所有活性治疗均显著优于安慰剂。
  • 对于ACR20/50,所有考察类别的生物制剂单药与生物制剂联合甲氨蝶呤之间未显示统计学显著差异。
  • IL-17抑制剂与IL-23抑制剂相当,且IL-17抑制剂在ACR20上显著优于TNF抑制剂。
  • 尽管受限于较少试验,TNF抑制剂、IL-23抑制剂和IL-17抑制剂在ACR50/70上无统计学差异。

临床怎么用

  • 原文结论指出,甲氨蝶呤与生物制剂联用并未改善ACR疗效结局,相比生物制剂单药治疗。
  • 原文结论指出,在银屑病关节炎患者中使用生物制剂以达到ACR20/50应答时,甲氨蝶呤似乎并非必要的背景治疗。

局限性

  • ACR50/70的分析受限于较少试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: An important consideration in the treatment of patients with psoriatic arthritis (PsA) is whether the addition of methotrexate (MTX) to biologics has greater efficacy than biologic monotherapy with respect to efficacy outcomes in these patients. OBJECTIVES: To conduct a network meta-analysis (NMA) comparing biologics by treatment class with and without MTX for treatment of adults with active PsA. METHODS: A systematic literature review (SLR) identified randomised, double-blinded, controlled trials, and a Bayesian NMA compared biologics with and without MTX by treatment class (tumour necrosis factor inhibitors (TNFi), interleukin-23 inhibitors (IL-23i) and IL-17i). Efficacy outcomes included American College of Rheumatology 20%, 50% and 70% (ACR20, ACR50 and ACR70) improvement response. RESULTS: The SLR initially identified 31 studies, of which 17 met feasibility criteria for the NMA by containing the 'without MTX' subgroup. For ACR20 efficacy (the most robust assessment examined), all active treatments were significantly better than placebo. No statistically significant differences were demonstrated between biologic monotherapy (for all classes examined) and biologics in combination with MTX for ACR20/50. IL-17i were comparable to IL-23i, and IL-17i were significantly better than TNFi for ACR20. Although limited by fewer trials, TNFi, IL-23i and IL-17i were not statistically different for ACR50/70. CONCLUSIONS: Concomitant use of MTX and biologics did not improve ACR efficacy outcomes versus biologic monotherapy. MTX does not appear to be necessary as a background therapy when biologics are used for the achievement of ACR20/50 responses in patients with PsA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Reddy S, Ross S, et al. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. 2024. PMID: 38296801. doi:10.1136/rmdopen-2023-003423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。